Skip to Content
Merck
  • [Expression of cancer-testis antigen SCP-1 mRNA in human nasopharyngeal carcinoma].

[Expression of cancer-testis antigen SCP-1 mRNA in human nasopharyngeal carcinoma].

Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery (2007-07-05)
Min Yi, Hong Liao, Shaoming Huang, Xiaoxun Xie, Guorong Luo
ABSTRACT

To investigate the gene expression of Cancer-Testis Antigen SCP-1 in human nasopharyngeal carcinoma. The SCP-1 mRNA were examined in the tumor tissues of 28 nasopharyngeal carcinoma cases and control pharynx vasitis tissues of 40 non-cancer cases by reverse transcriptase polymerase chain reaction. A randomized sample of positive expression of SCP-1 mRNA was extracted for DNA sequencing to examine the reliability of results. The correlation of the expression of SCP-1 mRNA with clinical data was analyzed by statistical method. The expression frequency of SCP-1 mRNA was 14.3% (4/28) in nasopharyngeal carcinoma and zero (0/40) in control pharynx vasitis tissue of non-cancer cases (P < 0.05); The DNA sequencing confirmed that the product of reverse transcriptase polymerase chain reaction was truly the target gene; No significant relationship was found between the expression of SCP-1 mRNA and clinical characters, such as age, gender and serum anti-EBV level (P > 0.05). SCP-1 mRNA is expressed in some nasopharyngeal carcinoma, suggesting that SCP-1 might be a new tumor target antigen of nasopharyngeal carcinoma.